PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-100.00%
Revenue decline while TRAW shows 0.00% growth. Joel Greenblatt would examine competitive position erosion.
8.54%
Cost growth of 8.54% while TRAW maintains flat costs. Bruce Berkowitz would investigate efficiency gap.
-83.05%
Gross profit decline while TRAW shows 0.00% growth. Joel Greenblatt would examine competitive position.
No Data
No Data available this quarter, please select a different quarter.
-18.94%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
28.45%
G&A growth less than half of TRAW's 61.04%. David Dodd would verify if efficiency advantage is structural.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.25%
Operating expenses reduction while TRAW shows 16.51% growth. Joel Greenblatt would examine advantage.
-7.93%
Total costs reduction while TRAW shows 16.60% growth. Joel Greenblatt would examine advantage.
-100.00%
Interest expense reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine advantage.
8.54%
D&A change of 8.54% while TRAW maintains D&A. Bruce Berkowitz would investigate efficiency.
7.52%
EBITDA growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
7.21%
Operating income growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-9.03%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
7.01%
Pre-tax income growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-68.42%
Tax expense reduction while TRAW shows 1.35% growth. Joel Greenblatt would examine advantage.
7.01%
Net income growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
8.82%
EPS growth while TRAW declines. John Neff would investigate advantages.
8.82%
Diluted EPS growth while TRAW declines. John Neff would investigate advantages.
0.91%
Share count reduction below 50% of TRAW's 0.19%. Michael Burry would check for concerns.
0.91%
Diluted share reduction below 50% of TRAW's 0.19%. Michael Burry would check for concerns.